{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies", "query": { "intervention": "Peripheral blood for correlative studies" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 617, "total_pages": 62, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+blood+for+correlative+studies&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T06:13:13.807Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Enzyme Inhibitor Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-10-03", "completion_date": "2022-10-30", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229278" }, { "nct_id": "NCT00244855", "title": "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "pharmacological study", "type": "OTHER" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2004-05", "completion_date": "2011-08-29", "has_results": true, "last_update_posted_date": "2017-05-22", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244855" }, { "nct_id": "NCT03011814", "title": "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Folliculotropic Mycosis Fungoides", "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Sezary Syndrome", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2017-03-08", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 4, "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03011814" }, { "nct_id": "NCT02827838", "title": "Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Human Papillomavirus Infection", "Stage I Oral Cavity Squamous Cell Carcinoma", "Stage I Oropharyngeal Squamous Cell Carcinoma", "Stage II Oral Cavity Squamous Cell Carcinoma", "Stage II Oropharyngeal Squamous Cell Carcinoma", "Stage III Oral Cavity Squamous Cell Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Oral Cavity Squamous Cell Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-01", "completion_date": "2022-04-22", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02827838" }, { "nct_id": "NCT00003789", "title": "Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Melanoma", "Stage III Melanoma" ], "interventions": [ { "name": "isolated limb perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "recombinant tumor necrosis factor family protein", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-16", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003789" }, { "nct_id": "NCT01987726", "title": "Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IV Breast Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2013-09-03", "completion_date": "2021-06-28", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01987726" }, { "nct_id": "NCT02428192", "title": "Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Leiomyosarcoma", "Unresectable Leiomyosarcoma", "Uterine Corpus Leiomyosarcoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2015-05-19", "completion_date": "2021-01-28", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02428192" }, { "nct_id": "NCT03186898", "title": "Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v7", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2018-01-26", "completion_date": "2027-02-04", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 27, "location_summary": "Atlanta, Georgia • Warrenville, Illinois • Baltimore, Maryland + 18 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03186898" }, { "nct_id": "NCT02766335", "title": "Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2014-07-31", "completion_date": "2020-09", "has_results": true, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 993, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 623 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766335" }, { "nct_id": "NCT00408408", "title": "Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride (Adriamycin)", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 1206, "start_date": "2006-11", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-09-26T06:13:13.807Z", "location_count": 432, "location_summary": "Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408408" } ] }